Gerald Schrenk

432 total citations
21 papers, 361 citations indexed

About

Gerald Schrenk is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Gerald Schrenk has authored 21 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 4 papers in Immunology and 3 papers in Genetics. Recurrent topics in Gerald Schrenk's work include Platelet Disorders and Treatments (15 papers), Hemophilia Treatment and Research (14 papers) and Blood Coagulation and Thrombosis Mechanisms (8 papers). Gerald Schrenk is often cited by papers focused on Platelet Disorders and Treatments (15 papers), Hemophilia Treatment and Research (14 papers) and Blood Coagulation and Thrombosis Mechanisms (8 papers). Gerald Schrenk collaborates with scholars based in Austria, United States and Netherlands. Gerald Schrenk's co-authors include Peter L. Turecek, Friedrich Scheiflinger, Hanspeter Rottensteiner, Katalin Váradi, Herbert Gritsch, H. P. Schwarz, Bruce M. Ewenstein, Frank Horling, Birgit M. Reipert and Peter Allacher and has published in prestigious journals such as Blood, Journal of Pharmacology and Experimental Therapeutics and Analytical and Bioanalytical Chemistry.

In The Last Decade

Gerald Schrenk

19 papers receiving 341 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gerald Schrenk Austria 9 315 58 55 43 28 21 361
Claude Négrier France 13 569 1.8× 67 1.2× 176 3.2× 8 0.2× 23 0.8× 29 607
Nives Selak Bienz Switzerland 7 516 1.6× 35 0.6× 157 2.9× 9 0.2× 30 1.1× 10 536
Raphael Teipel Germany 8 137 0.4× 59 1.0× 38 0.7× 12 0.3× 4 0.1× 21 196
Sammy Chebon Switzerland 11 698 2.2× 50 0.9× 219 4.0× 22 0.5× 41 1.5× 22 731
Kenji Nara Japan 5 121 0.4× 68 1.2× 35 0.6× 18 0.4× 9 0.3× 5 170
Natalie J. Jooss United Kingdom 9 122 0.4× 34 0.6× 11 0.2× 7 0.2× 21 0.8× 15 183
K R Reynolds United States 5 104 0.3× 66 1.1× 72 1.3× 6 0.1× 4 0.1× 10 190
L. Rusen United States 10 723 2.3× 93 1.6× 187 3.4× 9 0.2× 24 0.9× 20 742
Charles Lubianca Kohem Brazil 10 100 0.3× 21 0.4× 25 0.5× 34 0.8× 6 0.2× 26 319
Kyriaki Manousou Greece 9 47 0.1× 85 1.5× 26 0.5× 8 0.2× 12 0.4× 31 153

Countries citing papers authored by Gerald Schrenk

Since Specialization
Citations

This map shows the geographic impact of Gerald Schrenk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Schrenk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Schrenk more than expected).

Fields of papers citing papers by Gerald Schrenk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Schrenk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Schrenk. The network helps show where Gerald Schrenk may publish in the future.

Co-authorship network of co-authors of Gerald Schrenk

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Schrenk. A scholar is included among the top collaborators of Gerald Schrenk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Schrenk. Gerald Schrenk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Holik, Ann‐Katrin, et al.. (2024). An Automated pre-Dilution Setup for Von Willebrand Factor Activity Assays. BIO-PROTOCOL. 14(1352). e5059–e5059. 1 indexed citations
2.
Schrenk, Gerald, et al.. (2022). Selective human factor VIII activity measurement after analytical in‐line purification. Research and Practice in Thrombosis and Haemostasis. 6(7). e12821–e12821. 1 indexed citations
3.
Gritsch, Herbert, et al.. (2022). Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease. Journal of Blood Medicine. Volume 13. 649–662. 11 indexed citations
4.
Hartmann, Rudolf, et al.. (2020). A bispecific antibody demonstrates limited measurability in routine coagulation assays. Blood Coagulation & Fibrinolysis. 31(6). 353–365. 4 indexed citations
5.
Glantschnig, Helmut, Michael Dockal, Veronika Ehrlich, et al.. (2019). Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys. Journal of Pharmacology and Experimental Therapeutics. 371(1). 95–105. 3 indexed citations
6.
Hartmann, Rudolf, et al.. (2017). A Bispecific Antibody Lacks Measurability in Routine Coagulation Assays and Comparability to Factor VIII. Blood. 130. 1080–1080. 1 indexed citations
7.
8.
Bonazza, Klaus, Hanspeter Rottensteiner, Gerald Schrenk, et al.. (2015). Ca2+ concentration-dependent conformational change of FVIII B-domain observed by atomic force microscopy. Analytical and Bioanalytical Chemistry. 407(20). 6051–6056. 9 indexed citations
9.
Turecek, Peter L., Srilatha Tangada, Herbert Gritsch, et al.. (2015). Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes. Expert Review of Clinical Pharmacology. 8(2). 163–177. 6 indexed citations
10.
Turecek, Peter L., J. Siekmann, Artur Mitterer, et al.. (2015). Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties. Blood. 126(23). 3536–3536. 3 indexed citations
11.
Hofbauer, Christoph J., Peter Allacher, Frank Horling, et al.. (2014). Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood. 125(7). 1180–1188. 98 indexed citations
12.
Schrenk, Gerald, et al.. (2014). Recombinant VWF Promotes Platelet Adhesion Under Shear Stress Dependent on Its Multimer Size. Blood. 124(21). 1442–1442.
13.
Bonazza, Klaus, Hanspeter Rottensteiner, Birgit Seyfried, et al.. (2013). Visualization of a protein-protein interaction at a single-molecule level by atomic force microscopy. Analytical and Bioanalytical Chemistry. 406(5). 1411–1421. 13 indexed citations
14.
Turecek, Peter L., M.J. Bossard, Michael Graninger, et al.. (2012). BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.. PubMed. 32 Suppl 1. S29–38. 86 indexed citations
15.
Gritsch, Herbert, Hanspeter Rottensteiner, Gerald Schrenk, et al.. (2012). BAX 855, a PEGylated rFVIII product with prolonged half-life. Hämostaseologie. 32(S 01). S29–S38. 40 indexed citations
16.
Auer, Wilfried, Hanspeter Rottensteiner, Gerald Schrenk, et al.. (2012). Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.. Blood. 120(21). 2233–2233. 1 indexed citations
17.
Rottensteiner, Hanspeter, Barbara Plaimauer, Gerald Schrenk, et al.. (2012). Functional Characterization of Baxter's Recombinant Human ADAMTS13 Drug Candidate.. Blood. 120(21). 2235–2235. 1 indexed citations
18.
Schrenk, Gerald, Katalin Váradi, Herbert Gritsch, et al.. (2011). Functional Characterization of BAX 855, a PEGylated Recombinant FVIII. Blood. 118(21). 4359–4359. 1 indexed citations
19.
Turecek, Peter L., Gerald Schrenk, Hanspeter Rottensteiner, et al.. (2010). Structure and Function of a Recombinant von Willebrand Factor Drug Candidate. Seminars in Thrombosis and Hemostasis. 36(5). 510–521. 43 indexed citations
20.
Schrenk, Gerald, Katalin Váradi, Hanspeter Rottensteiner, et al.. (2010). Binding of FVIII to Recombinant VWF. Blood. 116(21). 1408–1408. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claude Négrier Breakdown of academic impact, for papers by Nives Selak Bienz Breakdown of academic impact, for papers by Raphael Teipel Breakdown of academic impact, for papers by Sammy Chebon Breakdown of academic impact, for papers by Kenji Nara Breakdown of academic impact, for papers by Natalie J. Jooss Breakdown of academic impact, for papers by K R Reynolds Breakdown of academic impact, for papers by L. Rusen Breakdown of academic impact, for papers by Charles Lubianca Kohem Breakdown of academic impact, for papers by Kyriaki Manousou
Rankless by CCL
2026